Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



You'll Have to Hold This One for the Dividend

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Johnson & Johnson (NYSE: JNJ  ) gets a pass for the first quarter. No reason to sell, but nothing to get excited about, either.

A 1.5% year-over-year increase in adjusted earnings isn't that bad, but it basically came from cost cutting. Revenue decreased 0.2% year over year.

Consumer health-care products continue to need a bandage, with sales down 2.4%. The company is still struggling with issues from the ongoing recalls of over-the-counter products. Johnson & Johnson blamed the decrease on an "impact on production volumes," which I take as a good sign. It's not like its back up to full speed, and consumers aren't switching back from brands sold by Pfizer (NYSE: PFE  ) , Bayer, and others. Of course, Johnson & Johnson had better hurry up and get back up to full speed; the longer the delay, the harder it will be to woo consumers back.

Sales of medical devices, the company's largest segment, were lower, but that shouldn't have come as much of a shock, since the year-ago quarter included sales of drug eluting stents before Johnson & Johnson decided to abandon the space.

The pharmaceutical segment was the only area where sales were up in the quarter, but it was a tale of two geographies. Stateside sales were down 10.8% as the company deals with generic competition for antibiotic Levaquin and manufacturing issues with cancer drug Doxil, which has led to rationing.

In the rest of the world, pharmaceutical sales were up 16.5%, but that's slightly misleading since it includes the transfer of sales of Remicade from Merck (NYSE: MRK  ) after the dispute ended in a settlement.

If you're looking for a bright spot to hang onto until next earnings season, it's J&J's prostate cancer drug, Zytiga, which is quickly approaching blockbuster status, selling $200 million worldwide in the first quarter. With new data showing that it works in patients earlier in their disease progression, it should take sales away from Sanofi's (NYSE: SNY  ) Taxotere and potentially Dendreon's (Nasdaq: DNDN  ) Provenge, although the latter is hoping to show that successive treatments are better than either treatment individually.

The best reason to own Johnson & Johnson at this point is the solid 3.5% dividend yield. The health-care giant is a few years away from rapid sales increases that will drive the share price higher, but as this quarter showed, it's stable enough to justify owning it for the dividend alone while you wait.

Looking for more dividend plays? Here are nine companies Fool analysts think have the right mix of growth and income. Get the Fool's report for free.

Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Pfizer and creating a diagonal call position in Johnson & Johnson. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1864190, ~/Articles/ArticleHandler.aspx, 10/20/2016 4:22:09 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,162.35 -40.27 -0.22%
S&P 500 2,141.34 -2.95 -0.14%
NASD 5,241.83 -4.58 -0.09%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/20/2016 4:02 PM
JNJ $114.87 Up +0.28 +0.24%
Johnson and Johnso… CAPS Rating: ****
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
MRK $61.92 Up +0.05 +0.08%
Merck and Co. CAPS Rating: ****
PFE $32.54 Down -0.06 -0.18%
Pfizer CAPS Rating: ****
SNY $38.07 Up +0.55 +1.47%
Sanofi CAPS Rating: *****